Images List Premium Download Classic

Immunotherapy

Immunotherapy-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
Board Of Regents, The University Of Texas System
February 15, 2018 - N°20180045736

The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies ...
Compounds and methods for modulating pharmacokinetics
The Brigham And Women's Hospital, Inc.
February 15, 2018 - N°20180044396

Methods and compositions are described for management of the pharmacokinetic properties of active agents, e. G., therapeutic moieties, by conjugating, fusing, or non-direct linkage of the active agent to one or more wild-type or modified heparin-binding peptides (hb). Compounds may be administered to tissues including skin. Contemplated uses include treatment of disease, allergen immunotherapy, and immunization. Other aspects relate to ...
Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
The Johns Hopkins University
February 15, 2018 - N°20180043003

Antigen-specific t cells, including nave t cells, and including rare precursor cells are enriched and expanded in culture. Enrichment and expansion provides a platform for more effective immunotherapy by adoptive transfer, as well as platforms for personalizing immunotherapy by determining t cell reactivity with a library of candidate peptide antigens.
Immunotherapy Patent Pack
Download 225+ patent application PDFs
Immunotherapy Patent Applications
Download 225+ Immunotherapy-related PDFs
For professional research & prior art discovery
inventor
  • 225+ full patent PDF documents of Immunotherapy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Manufacture of peanut formulations for oral desensitization
Aimmune Therapeutics, Inc.
February 15, 2018 - N°20180042816

The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies.
Immunotherapy treatment kit and method of using the same
Phd Preventative Health Care And Diagnostics, Inc.
February 15, 2018 - N°20180042545

The invention generally relates to medical kits, e. G., an immunotherapy treatment and testing kits, and more particularly to a method of using the kits and system for treating allergies.
Beta-catenin inhibitors in cancer immunotherapy
The University Of Chicago
February 08, 2018 - N°20180038868

Provided herein are compositions and methods for the treatment of cancer by inhibition of β-catenin or a β-catenin pathway. In particular, inhibitors of β-catenin and/or the wnt/p-catenin signaling pathway are employed prevent or reverse evasion of immune response or immuno-therapy by cancers.
Immunotherapy Patent Pack
Download 225+ patent application PDFs
Immunotherapy Patent Applications
Download 225+ Immunotherapy-related PDFs
For professional research & prior art discovery
inventor
  • 225+ full patent PDF documents of Immunotherapy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
February 08, 2018 - N°20180037629

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated t-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor ...
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
February 08, 2018 - N°20180037628

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated t-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor ...
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
February 08, 2018 - N°20180037627

A method of treating a patient who has hepatocellular carcinoma (hcc), colorectal carcinoma (crc), glioblastoma (gb), gastric cancer (gc), esophageal cancer, nsclc, pancreatic cancer (pc), renal cell carcinoma (rcc), benign prostate hyperplasia (bph), prostate cancer (pca), ovarian cancer (oc), melanoma, breast cancer (brca), cll, merkel cell carcinoma (mcc), sclc, non-hodgkin lymphoma (nhl), aml, gallbladder cancer and cholangiocarcinoma (gbc, ccc), urinary ...
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
February 08, 2018 - N°20180037626

A method of treating a patient who has hepatocellular carcinoma (hcc), colorectal carcinoma (crc), glioblastoma (gb), gastric cancer (gc), esophageal cancer, nsclc, pancreatic cancer (pc), renal cell carcinoma (rcc), benign prostate hyperplasia (bph), prostate cancer (pca), ovarian cancer (oc), melanoma, breast cancer (brca), cll, merkel cell carcinoma (mcc), sclc, non-hodgkin lymphoma (nhl), aml, gallbladder cancer and cholangiocarcinoma (gbc, ccc), urinary ...
Immune system enhancing immunotherapy for the treatment of cancer
Panacea Pharmaceuticals
February 08, 2018 - N°20180036424

This application discloses immunoconjugates comprising antibodies against a particular target (such as cancer associated antigen or cancer specific antigen) that are conjugated with an immune enhancer, recruiter or solicitor. Also discloses are compositions and methods of using the inventive immunoconjugates to treat cancer.
Anti-tumor vaccine derived from normal cells
Cytovac A/s
February 08, 2018 - N°20180036397

A composition for inducing an immune response in a mammal, comprises lymphoid cells in which expression of tumor antigens has been chemically induced. The tumor antigens are induced in proliferating normal lymphoid cells, especially during the log phase of proliferation. The proliferation of the normal lymphoid cells is stimulated by normal mature dendritic cells. Most conveniently, the lymphoid cells are ...
Expansion of alloantigen-reactive regulatory t cells
The Regents Of The University Of California
February 08, 2018 - N°20180036345

The present disclosure relates generally to the manufacture of regulatory t cells (tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive tregs ex vivo. Alloantigen-reactive tregs produced in this way are suitable for the induction and/or maintenance of immunologic tolerance in recipients of allogeneic transplants.
Immunotherapy Patent Pack
Download 225+ patent application PDFs
Immunotherapy Patent Applications
Download 225+ Immunotherapy-related PDFs
For professional research & prior art discovery
inventor
  • 225+ full patent PDF documents of Immunotherapy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods and compositions for enhancing anti-ssea4 immunotherapy
February 01, 2018 - N°20180030124

A method for treating a tumor by administering an antibody or antibody fragment that binds specifically to stage-specific embryonic antigen 4, and an agent that enhances t cell anti-tumor responses. Also provided is a pharmaceutical composition for treating a tumor. The pharmaceutical composition contains an anti-ssea4 antibody or antibody fragment, an agent that enhances t cell responses, and a pharmaceutically acceptable ...
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
February 01, 2018 - N°20180030113

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated t-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor ...
Novel minor histocompatibility antigens and uses thereof
Rsem, Limited Partnership
February 01, 2018 - N°20180030112

Novel minor histocompatibility antigens (mihas) are described. These novel mihas were selected based on two features: (i) they are encoded by loci with a minor allele frequency (maf) of at least 0. 05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel mihas are also described. The present application also discloses the use of these ...
Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
Tyrnovo Ltd.
February 01, 2018 - N°20180028475

Provided is a treatment of cancer using a dual modulator of insulin receptor substrate (irs) and signal transducer and activator of transcription 3 (stat3), as well with other agents. The combination can be used to treat a tumor that has developed resistance to an egfr inhibitor, egfr antibody, mtor inhibitor, mek inhibitor, mutated b-raf inhibitor, chemotherapeutic agents, and certain combinations thereof, ...
Chimeric antigen receptors with an optimized hinge region
Chemotherapeutisches Forschungsinstitut Georg-speyer-haus
January 25, 2018 - N°20180022828

The present invention relates to multi-functional proteins which comprise (i) a signal peptide, (ii) a target specific recognition domain, (iii) a linker region, connecting domain (ii) and domain (iv) which comprises a specific modified hinge region of the human cd8 alpha-chain, and (iv) an effector domain. The present invention furthermore relates to nucleic acids encoding the proteins, expression constructs for ...
Novel anti-fibroblast activation protein (fap) binding agents and uses thereof
Mabimmune Diagnostics Ag
January 25, 2018 - N°20180022822

Provided are novel human-derived antibodies specific for fibroblast activation protein (fap), preferably capable of selectively inhibiting the enzymatic activity of fap, and chimeric antigen receptors (cars) directed against the human fap antigen as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with fap are provided. Assays and kits ...
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
The Trustees Of The University Of Pennsylvania
January 25, 2018 - N°20180022795

The present invention provides compositions and methods for regulating the specificity and activity of t cells. In one embodiment, the invention provides a type of chimeric antigen receptor (car) wherein the car is termed a “kir-car” which is a car design comprising a component of a receptor naturally found on natural killer (nk) cells. In one ...
Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
Immune Biosolutions Inc.
January 25, 2018 - N°20180022784

It is described a clostridium difficile (c-difficile) toxins a and/or b as a target for therapy, including passive immunotherapy, and particularly prevention of c-difficile intoxication in human or other animals. It is also described a polypeptide comprising a portion of c-difficile toxins a and/or b sequence being an epitope for anti-toxins a and/or b antibody. It disclosed ...
Loading